Table of Contents Author Guidelines Submit a Manuscript
Journal of Cancer Epidemiology
Volume 2015, Article ID 203284, 7 pages
http://dx.doi.org/10.1155/2015/203284
Research Article

Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast

1Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA
2Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London W2 1PG, UK
3Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
4David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
5Department of Oncology, McGill University, Montreal, QC, Canada H3A 0G4
6Population Studies and Prevention Program, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
7Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA

Received 6 February 2015; Accepted 12 May 2015

Academic Editor: Brian Cox

Copyright © 2015 Chelsea Catsburg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. A. N. Silvera and T. E. Rohan, “Benign proliferative epithelial disorders of the breast: a review of the epidemiologic evidence,” Breast Cancer Research and Treatment, vol. 110, no. 3, pp. 397–409, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. M. J. Worsham, J. Abrams, U. Raju et al., “Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population,” Breast Journal, vol. 13, no. 2, pp. 115–121, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. G. C. Kabat, J. G. Jones, N. Olson et al., “A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer,” Cancer Causes and Control, vol. 21, no. 6, pp. 821–828, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. L. Cote, J. J. Ruterbusch, B. Alosh et al., “Benign breast disease and the risk of subsequent breast cancer in African American women,” Cancer Prevention Research, vol. 5, no. 12, pp. 1375–1380, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. S. R. Lakhani, “The transition from hyperplasia to invasive carcinoma of the breast,” Journal of Pathology, vol. 187, no. 3, pp. 272–278, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Rohan and R. Kandel, “Breast,” in Cancer Precursors: Epidemiology, Detection, and Prevention, E. L. Franco and T. E. Rohan, Eds., pp. 232–248, Springer, New York, NY, USA, 2002. View at Google Scholar
  7. S. J. R. Dean, C. M. Perks, J. M. P. Holly et al., “Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer,” American Journal of Clinical Pathology, vol. 141, no. 3, pp. 323–333, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. R. C. Baxter, “IGF binding proteins in cancer: mechanistic and clinical insights,” Nature Reviews Cancer, vol. 14, no. 5, pp. 329–341, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. E. J. Foulstone, L. Zeng, C. M. Perks, and J. M. P. Holly, “Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor,” Endocrinology, vol. 154, no. 5, pp. 1780–1793, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Hoeflich, R. Reisinger, H. Lahm et al., “Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?” Cancer Research, vol. 61, no. 24, pp. 8601–8610, 2001. View at Google Scholar · View at Scopus
  11. W. J. Azar, S. Zivkovic, G. A. Werther, and V. C. Russo, “IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells,” Oncogene, vol. 33, no. 5, pp. 578–588, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Ko, H. K. Park, S. Yang, E. Y. Kim, S. C. Chung, and I. T. Hwang, “Association between insulin-like growth factor binding protein-2 levels and cardiovascular risk factors in Korean children,” Endocrine Journal, vol. 59, no. 4, pp. 335–343, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. C. M. Friedenreich, H. E. Bryant, F. Alexander, J. Hugh, J. Danyluk, and D. L. Page, “Risk factors for benign proliferative breast disease,” International Journal of Epidemiology, vol. 29, no. 4, pp. 637–644, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Catsburg, M. J. Gunter, C. Chen et al., “Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease,” Cancer Research, vol. 74, no. 12, pp. 3248–3258, 2014. View at Google Scholar
  15. H. L. Judd, I. M. Shamonki, A. M. Frumar, and L. D. Lagasse, “Origin of serum estradiol in postmenopausal women,” Obstetrics and Gynecology, vol. 59, no. 6, pp. 680–686, 1982. View at Google Scholar · View at Scopus
  16. T. J. Key, “Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women,” Steroids, vol. 76, no. 8, pp. 812–815, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Juncker-Jensen, A. E. Lykkesfeldt, J. Worm, U. Ralfkiær, U. Espelund, and J. S. Jepsen, “Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator,” Growth Hormone and IGF Research, vol. 16, no. 4, pp. 224–239, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Ruan and M. Lai, “Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome?” Acta Diabetologica, vol. 47, no. 1, pp. 5–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. N. Rajpathak, M. He, Q. Sun et al., “Insulin-like growth factor axis and risk of type 2 diabetes in women,” Diabetes, vol. 61, no. 9, pp. 2248–2254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. The Women’s Health Initiative Study Group, “Design of the Women's Health Initiative clinical trial and observational study,” Controlled Clinical Trials, vol. 19, no. 1, pp. 61–109, 1998. View at Publisher · View at Google Scholar
  21. J. Hays, J. R. Hunt, F. A. Hubbell et al., “The Women's Health Initiative recruitment methods and results,” Annals of Epidemiology, vol. 13, no. 9, supplement, pp. S18–S77, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. T. E. Rohan, A. Negassa, R. T. Chlebowski et al., “Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial,” Journal of the National Cancer Institute, vol. 100, no. 8, pp. 563–571, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Cui, D. L. Page, R. T. Chlebowski et al., “Alcohol and folate consumption and risk of benign proliferative epithelial disorders of the breast,” International Journal of Cancer, vol. 121, no. 6, pp. 1346–1351, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. W. D. Dupont and D. L. Page, “Risk factors for breast cancer in women with proliferative breast disease,” The New England Journal of Medicine, vol. 312, no. 3, pp. 146–151, 1985. View at Publisher · View at Google Scholar · View at Scopus
  25. S. J. Schnitt, J. L. Connolly, F. A. Tavassoli et al., “Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria,” The American Journal of Surgical Pathology, vol. 16, no. 12, pp. 1133–1143, 1992. View at Publisher · View at Google Scholar · View at Scopus
  26. M. K. Sidawy, M. H. Stoler, W. J. Frable et al., “Interobserver variability in the classification of proliferative breast lesions by fine-needle aspiration: results of the Papanicolaou society of cytopathology study,” Diagnostic Cytopathology, vol. 18, no. 2, pp. 150–165, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. C. A. Bodian, K. H. Perzin, R. Lattes, and P. Hoffmann, “Reproducibility and validity of pathologic classifications of benign breast disease and implications for clinical applications,” Cancer, vol. 71, no. 12, pp. 3908–3913, 1993. View at Google Scholar · View at Scopus
  28. B. Langholz and L. Goldstein, “Risk set sampling in epidemiologic cohort studies,” Statistical Science, vol. 11, no. 1, pp. 35–53, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. R. A. Krajcik, N. D. Borofsky, S. Massardo, and N. Orentreich, “Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 12, pp. 1566–1573, 2002. View at Google Scholar · View at Scopus
  30. H. Grønbæk, A. Flyvbjerg, L. Mellemkjær et al., “Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women,” Cancer Epidemiology Biomarkers and Prevention, vol. 13, no. 11, part 1, pp. 1759–1764, 2004. View at Google Scholar · View at Scopus
  31. R. Kaaks, E. Lundin, J. Manjer et al., “Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden,” Cancer Causes & Control, vol. 13, no. 4, pp. 307–316, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Keinan-Boker, H. B. B. de Mesquita, R. Kaaks et al., “Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer,” International Journal of Cancer, vol. 106, no. 1, pp. 90–95, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Muti, T. Quattrin, B. J. B. Grant et al., “Fasting glucose is a risk factor for breast cancer: a prospective study,” Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 11, pp. 1361–1368, 2002. View at Google Scholar · View at Scopus
  34. N. M. Probst-Hensch, J. H. B. Steiner, P. Schraml et al., “IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity,” Clinical Cancer Research, vol. 16, no. 3, pp. 1025–1032, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. B. S. Schütt, M. Langkamp, U. Rauschnabel, M. B. Ranke, and M. W. Elmlinger, “Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells,” Journal of Molecular Endocrinology, vol. 32, no. 3, pp. 859–868, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. K. W. Frommer, K. Reichenmiller, B. S. Schutt et al., “IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T,” Journal of Molecular Endocrinology, vol. 37, no. 1, pp. 13–23, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Diehl, E. Hessel, D. Oesterle et al., “IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis,” International Journal of Cancer, vol. 124, no. 9, pp. 2220–2225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. C. M. Boney, B. M. Moats-Staats, A. D. Stiles, and A. J. D'Ercole, “Expression of insulin-like growth factor-I (IGF-I) and IGF-binding proteins during adipogenesis,” Endocrinology, vol. 135, no. 5, pp. 1863–1868, 1994. View at Publisher · View at Google Scholar · View at Scopus
  39. S. B. Wheatcroft, M. T. Kearney, A. M. Shah et al., “IGF-binding protein-2 protects against the development of obesity and insulin resistance,” Diabetes, vol. 56, no. 2, pp. 285–294, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Hu, L. Pawlikowska, A. Kanaya et al., “Serum insulin-like growth factor-1 binding proteins 1 and 2 and mortality in older adults: the health, aging, and body composition study,” Journal of the American Geriatrics Society, vol. 57, no. 7, pp. 1213–1218, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. R. M. Martin, J. M. P. Holly, G. D. Smith, and D. Gunnell, “Associations of adiposity from childhood into adulthood with insulin resistance and the insulin-like growth factor system: 65-year follow-up of the Boyd Orr cohort,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3287–3295, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. J. D. Yager and N. E. Davidson, “Estrogen carcinogenesis in breast cancer,” The New England Journal of Medicine, vol. 354, no. 3, pp. 270–282, 2006. View at Publisher · View at Google Scholar · View at Scopus